The U.S. Food and Drug Administration stands at a crossroads. It may soon broaden a little-known exemption. This change could let certain toxic compounds enter the food chain without prior safety vetting.

Under the proposal, substances deemed non-carcinogenic could bypass rigorous review if present below 0.5 parts per billion. The threshold of regulation exemption already applies to food packaging and processing equipment. Now regulators consider extending it further. Experts warn the move undercuts decades of consumer safeguards.

The Threshold That Divides Safety From Risk

The Guardian analysis lays bare the stakes. Campaigners point to hormone disruptors. These chemicals damage developing brains and reproductive systems at doses far below the proposed cutoff. Perchlorate offers one stark example. Used in rocket fuel, it once leached from treated grain bags into children’s cereal. Levels spiked. Potential for brain damage followed.

Phthalates, certain bisphenols, some PFAS forever chemicals and flame retardants fall into the same category. They don’t cause cancer in the classic sense. Yet their effects appear at trace amounts. The definition of “appreciable risk” drives the dispute. FDA calculations assume safety below that 0.5 ppb line. Independent scientists disagree.

Maricel Maffini, a toxicologist who has tracked FDA decisions for years, co-authored a 2026 review with the Environmental Working Group. It uncovered at least 111 food chemicals exploiting the GRAS loophole. These substances appear across thousands of products. Companies self-determine safety. They often cite obscure studies or consultants paid to affirm low risk. Public announcements hide deep on corporate websites.

But the agency isn’t idle. On October 8, 2026, the FDA finalized its proactive post-market assessment program for food chemicals. It launched reassessments of butylated hydroxytoluene, or BHT, and azodicarbonamide, known as ADA. Both additives preserve fats in cereals, frozen foods and baked goods. The FDA announcement described a systematic process. It monitors signals on hazards, exposure and use. Then it prioritizes, evaluates and manages risks.

Officials framed the steps as protection. “This systematic, transparent approach helps protect public health and reinforces the rigorous safety standards that protect American consumers,” one statement read. Public comments on BHT and ADA closed months ago. Data poured in from manufacturers, researchers and everyday citizens.

Contrast that activity with the TOR proposal. Advocates see contradiction. One hand tightens review on known additives. The other hand may loosen entry for new or unexamined compounds. Robert F. Kennedy Jr., as health secretary, has pushed a “Make America Healthy Again” agenda. It promises fewer chemicals overall. Yet this exemption expansion appears to run counter.

Recent testing adds layers. The FDA’s largest-ever survey of infant formula, results released in April 2026 and discussed in Contemporary Pediatrics coverage, examined 312 samples across 16 brands. Mercury stayed undetectable in 95% of them. Pesticides vanished in 99%. Heavy metals registered low. Lead mostly below 0.5 ppb. PFAS appeared rarely, in parts per trillion.

Those findings reassure parents. They also spotlight the gap. Regulators celebrate low detections while debating rules that could permit higher ones elsewhere. PFAS data from the Total Diet Study tells a similar story. Over 95% of fresh and processed foods showed no detections. Trace amounts turned up in seafood, meats, dairy and kale. The Environmental Working Group statement from September 30, 2026, pulled no punches. Scott Faber, EWG senior vice president for government affairs, said the FDA “cannot afford to wait one more day to set action levels for PFAS in our food, as other nations have done.”

For millions, food—not water—delivers the main PFAS dose. The compounds accumulate. They link to immune problems, cancer and developmental delays. FDA officials once declared current levels posed “no food safety risk.” Critics called it dismissal of their own scientists’ data.

And the GRAS system? It lets companies introduce ingredients without FDA sign-off. They simply declare them generally recognized as safe. A New York Times report from August detailed proposed fixes. Companies would notify the agency of new additives and submit safety evidence. Yet the rule wouldn’t force retroactive data on thousands of existing substances. Self-determination survives.

So the TOR expansion lands amid mixed signals. FDA modernizes pesticide monitoring. It updates compliance programs for infant foods. It sets action levels for cadmium and arsenic in baby products. All positive steps. But loosening the threshold for direct food additives risks undoing gains.

Perchlorate in cereal. Phthalates in packaging that migrate. Flame retardants that dust food surfaces. Each carries exposure routes the 0.5 ppb line may miss. Children’s bodies absorb more per body weight. Their brains develop rapidly. Harm compounds over time.

Industry pushes back quietly. Safety data often comes from consultants with ties to the very companies seeking approval. “Widely accepted” research sometimes means industry-funded. Advocates demand independent science. They want enforceable limits, not voluntary phase-outs.

The FDA’s post-market program could catch problems later. Signals trigger review. Reassessments follow. Yet prevention beats cure. Especially when the cure involves pulling products already on shelves or in pantries.

Recent X discussions echo the alarm. Users shared the Guardian piece widely over the weekend of October 10-11. They questioned alignment with health agendas. One post called the loophole “a gift to big food.” Others demanded transparency.

Regulators face pressure from all sides. Consumer groups. Public health researchers. Food manufacturers wary of new testing costs. Lawmakers watching election-year optics. The decision on TOR won’t come in isolation. It will shape trust in the food supply for years.

Low contaminant results in infant formula buy time. They don’t erase underlying vulnerabilities. Hormone disruption doesn’t announce itself with acute illness. It unfolds slowly. Across populations. In metrics like IQ points lost or fertility rates shifted.

Expansion of the exemption could open floodgates. Not for known carcinogens. For the subtler threats. The ones that slip past old definitions. Science has advanced. Testing detects smaller amounts. Toxicology understands low-dose effects better. Policy lags.

FDA leaders insist any change rests on evidence. They point to the new assessment framework as proof of seriousness. Reassessing BHT and ADA shows willingness to revisit old approvals. Yet the proposal itself suggests comfort with higher tolerances for certain risks.

Critics won’t let the contradiction slide. They cite the 111 GRAS exploits. The perchlorate precedent. The PFAS persistence. Each case builds the argument against expansion. Safety shouldn’t hinge on a single number. Or on whether a chemical causes tumors in rats.

Broader reforms hover. Stronger post-market surveillance. Mandatory notifications. Independent review panels. Bans on certain classes outright. The agency has tools. The question is whether it will use them aggressively.

America’s food system feeds hundreds of millions. It also exposes them to thousands of synthetic compounds. Balancing those realities demands precision. Not loopholes. The coming decision on the threshold of regulation will signal which path regulators choose.